Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
BioNTech SE - American Depositary Shares
(NQ:
BNTX
)
99.71
+3.17 (+3.28%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 25, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about BioNTech SE - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
70
71
Next >
BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3
↗
November 04, 2024
BioNTech's Q3 revenue surged to €1.244 billion, reflecting early COVID-19 vaccine approvals. Net profit rose to €198.1 million, and full-year guidance adjusted downward.
Via
Benzinga
BioNTech Jumps On Surprise Profit, Wide Sales Beat; But Lowers Outlook
↗
November 04, 2024
The company now expects sales to come in at the lower end of its previous guidance.
Via
Investor's Business Daily
BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update
November 04, 2024
From
BioNTech SE
Via
GlobeNewswire
As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report
↗
November 01, 2024
Amid the election, and a Fed rate vote, earnings season roars ahead.
Via
Investor's Business Daily
Topics
Economy
Stocks
Forecasting The Future: 15 Analyst Projections For BioNTech
↗
October 07, 2024
Via
Benzinga
Forecasting The Future: 8 Analyst Projections For BioNTech
↗
September 13, 2024
Via
Benzinga
Market Whales and Their Recent Bets on BNTX Options
↗
September 13, 2024
Via
Benzinga
BioNTech to Host Innovation Series R&D Day on November 14, 2024
October 31, 2024
From
BioNTech SE
Via
GlobeNewswire
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?
↗
October 24, 2024
This drugmaker's lead candidate could become a top-selling cancer therapy.
Via
The Motley Fool
FDA Presses Clinical Hold Button For BioNTech's Partner Late-Stage Trial Of Investigational Lung Cancer Treatment
↗
October 21, 2024
BioNTech's Phase 3 NSCLC trial is paused after varying outcomes. Current participants continue treatment, and other trials remain unaffected.
Via
Benzinga
BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024
October 21, 2024
From
BioNTech SE
Via
GlobeNewswire
Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology
↗
October 17, 2024
Northwestern University has filed a lawsuit against Moderna, alleging the company used its patented lipid nanoparticle technology without permission in the development of its COVID-19 vaccines.
Via
Benzinga
Topics
Lawsuit
GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement
↗
October 15, 2024
GlaxoSmithKline has filed a lawsuit against Moderna, claiming its mRNA vaccines infringe on GSK's patents. GSK seeks royalties for Moderna's alleged unlicensed use of its groundbreaking vaccine...
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Pfizer Jumps After Activist Investor Starboard Reportedly Takes $1 Billion Stake
↗
October 07, 2024
Shares peaked near 62 in late 2021, but are now worth less than half of that.
Via
Investor's Business Daily
4 Reasons Pfizer Could Be a Value Play You Can't Miss
October 07, 2024
Pfizer Inc. (NYSE: PFE) hit its peak during the COVID-19 pandemic when its vaccines developed with BioNTech SE (NASDAQ: BNTX) sent shares surging up to $61.71
Via
MarketBeat
Uber To Rally Over 33%? Here Are 10 Top Analyst Forecasts For Monday
↗
October 07, 2024
Via
Benzinga
Consumer Tech News (Sept 30-Oct 4): Latest Windows 11 Update Causing Trouble, Apple Accused Of Compelling Employees To Sign Illegal Agreements & More
↗
October 06, 2024
Major tech companies lobby against CA bill regulating AI, Apple faces legal complaints, iPhone users retain devices longer. Google warns Apple app removal.
Via
Benzinga
Topics
Artificial Intelligence
Law Enforcement
Google DeepMind, BioNtech Unveil AI Lab Assistants To Revolutionize Scientific Research
↗
October 02, 2024
This AI aims to facilitate interdisciplinary collaboration and uncover unexpected connections in scientific research.
Via
Benzinga
Topics
Artificial Intelligence
BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day
October 01, 2024
From
BioNTech SE
Via
GlobeNewswire
Exxon Mobil To $120? Here Are 10 Top Analyst Forecasts For Tuesday
↗
September 24, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
↗
September 23, 2024
Via
Benzinga
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
↗
September 22, 2024
10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90%
Via
Benzinga
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
September 20, 2024
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
September 20, 2024
From
BioNTech SE
Via
GlobeNewswire
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
↗
September 17, 2024
BioNTech is developing a drug similar to Summit's and shares have skyrocketed over the past four trading days.
Via
Investor's Business Daily
BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024
September 17, 2024
From
BioNTech SE
Via
GlobeNewswire
Here's Why Everyone's Talking About Summit Therapeutics
↗
September 17, 2024
Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock.
Via
The Motley Fool
DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions
↗
September 16, 2024
Florida advises against mRNA Covid vaccines for vulnerable residents, citing safety concerns. Gov. DeSantis' administration urges healthcare providers to prioritize alternative vaccines for seniors and...
Via
Benzinga
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
↗
September 15, 2024
These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also raised price targets for Applovin and Arm Holdings.
Via
Benzinga
Should You Buy Novavax Stock After This Regulatory Win?
↗
September 13, 2024
The biotech continues to earn important wins, but is it enough?
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
70
71
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today